Advertisement
Canada markets open in 6 hours 13 minutes
  • S&P/TSX

    22,346.76
    -121.40 (-0.54%)
     
  • S&P 500

    5,307.01
    -14.40 (-0.27%)
     
  • DOW

    39,671.04
    -201.95 (-0.51%)
     
  • CAD/USD

    0.7307
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    77.22
    -0.35 (-0.45%)
     
  • Bitcoin CAD

    95,144.17
    -406.49 (-0.43%)
     
  • CMC Crypto 200

    1,515.39
    +12.73 (+0.85%)
     
  • GOLD FUTURES

    2,364.30
    -28.60 (-1.20%)
     
  • RUSSELL 2000

    2,081.71
    -16.65 (-0.79%)
     
  • 10-Yr Bond

    4.4340
    +0.0200 (+0.45%)
     
  • NASDAQ futures

    18,948.00
    +161.25 (+0.86%)
     
  • VOLATILITY

    12.29
    0.00 (0.00%)
     
  • FTSE

    8,374.29
    +3.96 (+0.05%)
     
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • CAD/EUR

    0.6752
    +0.0007 (+0.10%)
     

Xencor First Quarter 2024 Earnings: Misses Expectations

Xencor (NASDAQ:XNCR) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$12.8m (down 33% from 1Q 2023).

  • Net loss: US$68.0m (loss widened by 12% from 1Q 2023).

  • US$1.11 loss per share (further deteriorated from US$1.02 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Xencor Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 49%. Earnings per share (EPS) also missed analyst estimates by 43%.

Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are down 6.8% from a week ago.

Risk Analysis

Be aware that Xencor is showing 3 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.